Rallybio (RLYB) Interest Expenses (2020 - 2026)
Rallybio (RLYB) posted Interest Expenses of $749000.0 for Q1 2026, up 741.57% sequentially from $89000.0 in Q4 2025, and up 9262.5% YoY from $8000.0 in Q1 2025.
Rallybio (RLYB) Interest Expenses (2020 - 2026) Analysis & Trends
Rallybio has reported Interest Expenses for 7 years, with the latest figure at $749000.0 in Q1 2026.
- Quarterly Interest Expenses rose 9262.5% year-over-year to $749000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $749000.0 (up 9262.5% YoY) and the FY2025 annual result came in at $200000.0, down 99.8% from the prior year.
- Interest Expenses rose to $749000.0 in Q1 2026 per RLYB's latest filing, from $89000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $98.0 million in Q4 2024 and troughed at $1000.0 in Q3 2024.
- A 5-year average of $10.8 million and a median of $200000.0 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses jumped 39039.5% in 2023, then slumped 99.91% in 2025.
- Over 5 years, Interest Expenses stood at $200000.0 in 2022, then surged by 39039.5% to $78.3 million in 2023, then gained by 25.19% to $98.0 million in 2024, then plunged by 99.91% to $89000.0 in 2025, then soared by 741.57% to $749000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $749000.0, $89000.0, and $46000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Jun 30, 2026 | 2.35 Mn |
| Mar 31, 2026 | 749,000.00 |
| Mar 31, 2026 | 749,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 98.00 Mn |
| Dec 31, 2024 | 98.00 Mn |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Mar 31, 2024 | 79,000.00 |